Coronavirus Vaccine JV Gives Refana Option For Panacea Stake

 
• By Vibha Ravi

Private US firm Refana, which expects its first commercial foray through a COVID-19 vaccine it will develop with Panacea Biotec, has obtained an option to acquire a stake in the Indian firm, with marketing rights to be split with the partners' 50:50 joint venture.  

Handshake
Panacea's COVID-19 Partnership Has Potential To Become Something Bigger • Source: Shutterstock

More from India

More from Focus On Asia